Amarin Corporation plc ( AMRN) Stock. Should you Buy or Sell? $ 1.37
0.02 (1.44 %)
Amarin Corporation plc Analysis
Updated on 10-09-2022| Symbol | AMRN |
| Price | $1.37 |
| Beta | 1.853 |
| Volume Avg. | $3.69 M |
| Market Cap | $552.39 M |
| 52 Week Range | $1.09 - $5.52 |
Amarin Corporation plc opened the day at $1.37 which is +'1.44 % on yesterday's close. Amarin Corporation plc has a 52 week high of $5.52 and 52 week low of $1.09, which is a difference of $4.43. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $552.39 M and total net profit is $583187000 which means the company is trading at 0.95 times profit to market capitalization. Theoretically, if you were to buy Amarin Corporation plc for $552.39 M, it would take 15 years to get your money back. Amarin Corporation plc are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Amarin Corporation plc Stock Forecast - Is Amarin Corporation plc a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Buy | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -5.457 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -0.210 |
Valuing Amarin Corporation plc
| Price Book Value Ratio | 0.940 | Price To Book Ratio | 0.940 |
| Price To Sales Ratio | 1.147 | Price Earnings Ratio | -5.457 |
How liquid is Amarin Corporation plc
| Current Ratio | 1.989 |
| Quick Ratio | 1.264 |
Debt
| Debt Ratio | 0.404 | Debt Equity Ratio | 0.678 |
| Long Term Debt To Capitalization | 0.017 | Total Debt To Capitalization | 0.000 |
Latest news about Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.
Investors weren't happy with the company's decision to cease operations in a large country.
It's probably high time to look at your portfolio and see which growth stocks to sell. It has been a disappointing year on Wall Street, to say the least.
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.
Amarin has seen sales of its lone drug, Vascepa, plummet against generic competition. Famed activist investor Alex Denner has recently taken a sizeable stake in the company.
About Amarin Corporation plc
Description :
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
